EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 1, 2020
Media advisory: The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2020.3177?guestAccessKey=0db3175b-46e7-4352-a0d0-035b3d96132b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090120
What The Viewpoint Says: The different ways treatment and research on psychiatric disorders have shifted because of COVID-19 are assessed in this Viewpoint, which suggests what changes should remain after the pandemic.
Authors: Carlos Blanco, M.D., Ph.D., of the National Institute on Drug Abuse in Bethesda, Maryland, is the corresponding author.
Editor’s Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.